Physician profile
Alexander J Ernst
NPI 1376923193
$6,038.69
in general payments reported to CMS, 2019-2025
39 companies · $2,360 in 2025
The $2,360 reported for 2025 was more than what 80% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $47.56 · 2021: $40.68 · 2022: $435 · 2023: $800 · 2024: $1,923 · 2025: $2,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,832 · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,831.82 |
| Education | $251.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $859.09 | 2019-2025 | |
| Genzyme Corporation | $764.45 | 2021-2025 | |
| Janssen Biotech, INC. | $696.14 | 2022-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $602.71 | 2019-2025 | |
| Leo Pharma INC. | $464.16 | 2023-2025 | Adbry, Anzupgo |
| Regeneron Healthcare Solutions, INC. | $329.23 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $246.72 | 2022-2025 | Opzelura |
| Glaxosmithkline, LLC. | $219.51 | 2019-2022 | |
| Galderma Laboratories, L.P. | $216.39 | 2024-2025 | Nemluvio |
| Ucb, INC. | $154.95 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $142.65 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $137.59 | 2023-2024 | Vtama |
| Genmab U.S., INC. | $131.96 | 2025 | Epkinly |
| Arcutis Biotherapeutics, INC. | $109.60 | 2023-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $94.99 | 2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $92.14 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $91.36 | 2023-2025 | Ilumya |
| Merck Sharp & Dohme LLC | $87.14 | 2020-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.08 | 2023-2025 | Spevigo |
| E.R. Squibb & Sons, L.L.C. | $51.76 | 2023-2024 | Sotyktu |
| Amgen INC. | $43.45 | 2024 | Repatha, Otezla |
| Exact Sciences Corporation | $39.87 | 2023-2025 | Cologuard Collection Kit |
| Abiomed | $39.35 | 2025 | |
| Organon LLC | $39.31 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $36.96 | 2025 | Natroba, Spinosad |
| Journey Medical Corporation | $24.25 | 2021 | |
| Novo Nordisk INC | $24.12 | 2025 | Rybelsus, Ozempic |
| Almirall LLC | $22.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.84 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.82 | 2025 | Opsumit, Uptravi |
| Mayne Pharma Commercial LLC | $21.59 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $19.43 | 2023 | Zilretta |
| Aimmune Therapeutics, INC. | $18.78 | 2025 | Zenpep |
| Sanofi Pasteur INC. | $17.93 | 2020 | |
| Boston Scientific Corporation | $17.81 | 2023 | |
| Alexion Pharmaceuticals, INC. | $17.45 | 2025 | Koselugo |
| Alk-Abello, INC | $16.49 | 2024 | Odactra, Grastek, Ragwitek |
| Esperion Therapeutics, INC. | $14.05 | 2025 | Nexletol |
| Seqirus USA INC | $13.50 | 2025 | Flucelvax, Fluad |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Ernst listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.